Results 81 to 90 of about 56,162 (258)

Upadacitinib in nail psoriasis: a case report

Journal of Dermatological Treatment, 2023
The purpose of the article Nail psoriasis is a refractory disease that affects 50–79% skin psoriasis patients and up to 80% of patients with psoriatic arthritis (PsA).
Na Wang, Qing Yang, Yongxia Liu, Hong Liu   +3 more
doaj   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

Alopecia areata: a multifactorial autoimmune condition [PDF]

, 2019
Alopecia areata is an autoimmune disease that results in non-scarring hair loss, and it is clinically characterised by small patches of baldness on the scalp and/or around the body. It can later progress to total loss of scalp hair (Alopecia totalis) and/
Butcher, John P., Henriquez, Fiona L., Reid, Stuart, Simakou, Teontor   +3 more
core   +1 more source

LNK (SH2B3): paradoxical effects in ovarian cancer. [PDF]

, 2015
LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined
Chien, W, Ding, L-W, Doan, NB, Dong, X-M, Garg, M, Gery, S, Hattori, N, Huang, RY-J, Koeffler, HP, Lin, D-C, Liu, L-Z, Meng, X, Said, JW, Sun, Q-Y, Tang, K, Xiao, J-F, Yang, H   +16 more
core   +5 more sources

Successful treatment of tofacitinib-refractory scleritis associated with multiple systemic inflammatory diseases using upadacitinib

Immunological Medicine
Scleritis is often associated with systemic inflammatory diseases, and a subset of patients remains refractory to conventional therapies, including corticosteroids, immunosuppressants, and tumor necrosis factor inhibitors (TNFi). Janus kinase inhibitors (
Kodai Yuge, Nobuyo Yawata, Kenichiro Asahara, Satoshi Yamana, Nobuyuki Ono, Koh-Hei Sonoda   +5 more
doaj   +1 more source

A High‐Sensitivity Circulating Nucleic Acid Sequencing Assay for Assessing Treatment Response to Alectinib in a Pediatric Patient With ALK‐Rearranged Non–Small Cell Lung Cancer

Pediatric Blood &Cancer, EarlyView.
Alberto D. Guerra, Nicholas F. Evageliou, Vandana Batra, Kristen L. Dalton, Stephanie Ortel, Usman Ashraf, Tricia R. Bhatti, Lisa J. States, Lea F. Surrey, Theodore W. Laetsch   +9 more
wiley   +1 more source

Efficacy and Safety Analysis of Roxarestat in Regulating Renal Anemia in Patients on Maintenance Hemodialysis

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley   +1 more source

LNK suppresses interferon signaling in melanoma. [PDF]

, 2019
LNK (SH2B3) is a key negative regulator of JAK-STAT signaling which has been extensively studied in malignant hematopoietic diseases. We found that LNK is significantly elevated in cutaneous melanoma; this elevation is correlated with hyperactive ...
Ding, Ling-Wen, Doan, Ngan, Edwards, Jarem J, Fernández, Lucia Torres, Koeffler, H Phillip, Lin, De-Chen, Loh, Xin-Yi, Mullins, David W, Pein, Maren, Ran, Xue-Bin, Said, Jonathan W, Scolyer, Richard A, Sun, Qiao-Yang, Thompson, John F, Venkatachalam, Nachiyappan, Wilmott, James S, Xiao, Jin-Fen, Xu, Liang, Yang, Henry, Zhou, Si-Qin   +19 more
core  

A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies [PDF]

, 2020
With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated.
Alikhan, Mujahed, Jogi, Reena, Nguyen, Julie K, Patel, Anisha B, Schlichte, Megan J   +4 more
core  

Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti‐MDA5 Dermatomyositis–Related Interstitial Lung Disease: A Pilot Study

ACR Open Rheumatology
Objective To evaluate the clinical characteristics and serum cytokine profiles of patients with anti‐MDA5 antibody–positive dermatomyositis with interstitial lung disease (MDA5+ DM‐ILD) treated with JAK inhibitors and to compare survivors and ...
Haruna Matsuo, Tomohiro Koga, Toshimasa Shimizu, Hiroyuki Ide, Serina Koto, Kanako Kojima, Yuya Fujita, Momoko Okamoto, Ayuko Takatani, Takahisa Suzuki, Yuta Matsushita, Atsushi Kawakami   +11 more
doaj   +1 more source